PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the publication of its abstract on preclinical studies of PDS0102 at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program being held May 29-31, 2020. The abstract confirms the ability of the Versamune® platform to induce powerful killer T-cell responses across tumor types.
Versamune® is a proprietary T-cell activating platform technology designed to train the immune system to detect and attack cancer cells. The published data demonstrate that Versamune®, when combined with the proprietary T-cell receptor gamma alternate reading frame protein (TARP), has the ability to activate a powerful killer T-cell response which specifically recognizes and attacks TARP-expressing cancer cells. PDS0102 is being developed to treat prostate and breast cancers, the majority of which express the TARP protein. The results of this study mirror the anti-HPV responses observed with the company’s lead program, PDS0101 which is entering Phase 2 for HPV-associated cancers.
“These data being presented at ASCO are significant for our oncology portfolio and highlight the versatility of our Versamune® platform in immuno-oncology,” commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. “Our ongoing studies continue to demonstrate the ability of our Versamune® platform to induce higher levels of potent, cancer-attacking T-cells in vivo compared to other immunotherapy technologies.”
Abstract e15211: “R-DOTAP (Versamune®): A Novel Enantiospecific Cationic Lipid Nanoparticle That Induces CD4 and CD8 Cellular Immune Responses to Whole Protein and Tumor-Specific Peptide Antigens” is available on the ASCO meeting website at abstracts.asco.org.